Mladsi D, Zhou X, Mader G, Sanon M, Wang J, Barnett C, Willey C, Seliger S. Mortality risk in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2024 Feb 16;25(1):56. doi: 10.1186/s12882-024-03484-3
Danese D, Goss D, Romano (DeMuro) C, Gupta C. Qualitative assessment of the patient experience of primary hyperoxaluria type 1: an observational study. BMC Nephrol. 2023 Oct 26;24(1):319. doi: 10.1186/s12882-023-03365-1
Mader G, Mladsi D, Sanon M, Purser M, Barnett CL, Oberdhan D, Watnick T, Seliger S. A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease. BMC Nephrol. 2022 Oct 18;23(1):334. doi: 10.1186/s12882-022-02956-8
Ajmera MR, Boscoe A, Mauskopf J, Candrilli SD, Levy M. Evaluation of comorbidities and health care resource use among patients with highly active neuromyelitis optica. J Neurol Sci. 2018 Jan;384(2018):96-103. doi: 10.1016/j.jns.2017.11.022
Smith RB, Bennett JE, Rantakokko P, Martinez D, Nieuwenhuijsen MJ, Toledano MB. The relationship between MX [3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone], routinely monitored trihalomethanes, and other characteristics in drinking water in a long-term survey. Environ Sci Technol. 2015 Jun 2;49(11):6485-93. doi: 10.1021/es5062006
Perez L, Medina-Ramon M, Kunzli N, Alastuey A, Pey J, Perez N, Garcia R, Tobias A, Querol X, Sunyer J. Size fractionate particulate matter, vehicle traffic, and case-specific daily mortality in Barcelona, Spain. Environ Sci Technol. 2009 Jul 1;43(13):4707-14. doi: 10.1021/es8031488
Poulos C, Whittington D. Time preferences for life-saving programs: evidence from six less developed countries. Environ Sci Technol. 2000 Apr 15;34(8):1445-55.